Table 1.
Cohort characteristics by SSRI exposure group. Note that small numbers (<20) were obscured to protect patient identities.
| Characteristic | S1R agonist SSRI exposure N = 1521a | Non-S1R agonist SSRI exposure N = 1803a | Unexposed N = 14584a |
|---|---|---|---|
| Sex | |||
| Male | 341 (22%) | 476 (26%) | 5641 (39%) |
| Female | 1180 (78%) | 1327 (74%) | 8943 (61%) |
| Age, median (years) | |||
| Age (years) | 826 (54%) | 883 (49%) | 7006 (48%) |
| 18-49 | 194 (13%) | 311 (17%) | 2332 (16%) |
| ≥ 70 | 286 (19%) | 341 (19%) | 2765 (19%) |
| 50-59 | 215 (14%) | 268 (15%) | 2481 (17%) |
| 60-69 | |||
| BMI, median (kg/m2) | 166 (11%) | 195 (11%) | 1957 (13%) |
| BMI (kg/m2) | 382 (25%) | 424 (24%) | 2518 (17%) |
| < 25 | 339 (22%) | 393 (22%) | 3595 (25%) |
| ≥ 40 | 373 (25%) | 454 (25%) | 3457 (24%) |
| 25-29 | 249 (16%) | 322 (18%) | 2250 (15%) |
| 30-34 | 12 (0.8%) | 15 (0.8%) | 807 (5.5%) |
| 35-39.9 | |||
| Missing | 1177 (77%) | 1367 (76%) | 9860 (68%) |
| Race and ethnicity | 25 (1.6%) | 24 (1.3%) | 309 (2.1%) |
| White Non-Hispanic | 208 (14%) | 289 (16%) | 3094 (21%) |
| Asian Non-Hispanic | 62 (4.1%) | 88 (4.9%) | 899 (6.2%) |
| Black or African American Non-Hispanic | 49 (3.2%) | 35 (1.9%) | 422 (2.9%) |
| Hispanic or Latino Any Race | 54 (3.6%) | 102 (5.7%) | 630 (4.3%) |
| Other Non-Hispanic / Unknown | 141 (9.3%) | 217 (12%) | 1181 (8.1%) |
| Myocardial infarction | 99 (6.5%) | 138 (7.7%) | 641 (4.4%) |
| Congestive heart failure | 42 (2.8%) | 70 (3.9%) | 245 (1.7%) |
| Cerebrovascular disease | 434 (29%) | 512 (28%) | 2967 (20%) |
| Dementia | 301 (20%) | 455 (25%) | 2793 (19%) |
| Chronic lung disease | 171 (11%) | 281 (16%) | 1564 (11%) |
| Type II diabetes, uncomplicated | 176 (12%) | 270 (15%) | 1567 (11%) |
| Type II diabetes, complicated | 165 (11%) | 179 (9.9%) | 1009 (6.9%) |
| Kidney disease | 9 (0.6%) | 13 (0.7%) | 82 (0.6%) |
| Liver disease | 168 (11%) | 248 (14%) | 1621 (11%) |
| HIV infection | 208 (14%) | 270 (15%) | 2308 (16%) |
| Cancer | 289 (19%) | 250 (14%) | 586 (4.0%) |
| COVID-19 related hospitalization | 514 (34%) | 574 (32%) | 2113 (14%) |
| Baseline bupropion use | 99 (6.5%) | 116 (6.4%) | 392 (2.7%) |
| Baseline benzodiazepine use | 135 (8.9%) | 139 (7.7%) | 298 (2.0%) |
| Baseline tricyclic antidepressant use | 189 (12%) | 230 (13%) | 987 (6.8%) |
| Baseline antipsychotic use | 24 (1.6%) | 35 (1.9%) | 244 (1.7%) |
| Baseline SNRI use | 402 (26%) | 495 (27%) | 1931 (13%) |
| Baseline immunotherapy treatment | 24 (1.6%) | 46 (2.6%) | 372 (2.6%) |
| Baseline moderate to high affinity S1R ligand use | 1026 (67%) | 1215 (67%) | 8744 (60%) |
a
Statistics presented: n (%); median (IQR).